Thyrocare Technologies Limited has informed the Exchange about equity infusion in Think Health Diagnostics Private Limited, wholly owned subsidiary of the Company
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies held its Board meeting on May 7, 2026, approving several key matters. The Board recommended a final dividend of Rs. 7 per share for FY 2025-26, taking total dividend to Rs. 9.33 per share (post-bonus). M/s. Price Waterhouse Chartered Accountants LLP was appointed as the new statutory auditor for a 5-year term. Two directors resigned - Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, both citing pre-occupation and other commitments, with the company confirming no material reasons beyond those stated. Two new directors were appointed - Mr. Uday Patel Kadam and Mr. Gaurav Verma, both as Non-Executive, Non-Independent Directors effective May 8, 2026. The Board also approved equity infusion of up to Rs. 5.50 crores in its wholly-owned subsidiary Think Health Diagnostics Private Limited, and proposed amendments to the Memorandum of Association to align with the Companies Act 2013 and expand the company's objects clause to include broader healthcare and diagnostics activities.
The resignation of two directors and appointment of two new directors indicates board restructuring. The equity infusion in Think Health Diagnostics supports the subsidiary's plans for building an affordable diagnostics platform. The MOA alteration signals the company's intent to expand into broader healthcare services beyond its current diagnostic focus.